Sandra Ihne1,2,3, Caroline Morbach1,3,4, Laura Obici5, Giovanni Palladini6, Stefan Störk1,3,4. 1. Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital Würzburg, Würzburg, Germany. 2. Department of Internal Medicine II, Hematology, University Hospital Würzburg, Würzburg, Germany. 3. Comprehensive Heart Failure Center (CHFC), University and University Hospital Würzburg, Würzburg, Germany. 4. Department of Internal Medicine I, Cardiology, University Hospital Würzburg, Würzburg, Germany. 5. Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, V.le Golgi 19, 27100, Pavia, Italy. 6. Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, V.le Golgi 19, 27100, Pavia, Italy. giovanni.palladini@unipv.it.
Abstract
PURPOSE: Amyloidosis represents an increasingly recognized but still frequently missed cause of heart failure. In the light of many effective therapies for light chain (AL) amyloidosis and promising new treatment options for transthyretin (ATTR) amyloidosis, awareness among caregivers needs to be raised to screen for amyloidosis as an important and potentially treatable differential diagnosis. This review outlines the diversity of cardiac amyloidosis, its relation to heart failure, the diagnostic algorithm, and therapeutic considerations that should be applied depending on the underlying type of amyloidosis. RECENT FINDINGS: Non-biopsy diagnosis is feasible in ATTR amyloidosis in the absence of a monoclonal component resulting in higher detection rates of cardiac ATTR amyloidosis. Biomarker-guided staging systems have been updated to facilitate risk stratification according to currently available biomarkers independent of regional differences, but have not yet prospectively been tested. Novel therapies for hereditary and wild-type ATTR amyloidosis are increasingly available. The complex treatment options for AL amyloidosis are improving continuously, resulting in better survival and quality of life. Mortality in advanced cardiac amyloidosis remains high, underlining the importance of early diagnosis and treatment initiation. Cardiac amyloidosis is characterized by etiologic and clinical heterogeneity resulting in a frequently delayed diagnosis and an inappropriately high mortality risk. New treatment options for this hitherto partially untreatable condition have become and will become available, but raise challenges regarding their implementation. Referral to specialized centers providing access to extensive and targeted diagnostic investigations and treatment initiation may help to face these challenges.
PURPOSE:Amyloidosis represents an increasingly recognized but still frequently missed cause of heart failure. In the light of many effective therapies for light chain (AL) amyloidosis and promising new treatment options for transthyretin (ATTR) amyloidosis, awareness among caregivers needs to be raised to screen for amyloidosis as an important and potentially treatable differential diagnosis. This review outlines the diversity of cardiac amyloidosis, its relation to heart failure, the diagnostic algorithm, and therapeutic considerations that should be applied depending on the underlying type of amyloidosis. RECENT FINDINGS: Non-biopsy diagnosis is feasible in ATTRamyloidosis in the absence of a monoclonal component resulting in higher detection rates of cardiac ATTRamyloidosis. Biomarker-guided staging systems have been updated to facilitate risk stratification according to currently available biomarkers independent of regional differences, but have not yet prospectively been tested. Novel therapies for hereditary and wild-type ATTRamyloidosis are increasingly available. The complex treatment options for AL amyloidosis are improving continuously, resulting in better survival and quality of life. Mortality in advanced cardiac amyloidosis remains high, underlining the importance of early diagnosis and treatment initiation. Cardiac amyloidosis is characterized by etiologic and clinical heterogeneity resulting in a frequently delayed diagnosis and an inappropriately high mortality risk. New treatment options for this hitherto partially untreatable condition have become and will become available, but raise challenges regarding their implementation. Referral to specialized centers providing access to extensive and targeted diagnostic investigations and treatment initiation may help to face these challenges.
Entities:
Keywords:
AL amyloidosis; ATTR amyloidosis; Amyloid cardiomyopathy; Cardiac amyloidosis; Diagnostic algorithm; Heart failure with preserved ejection fraction (HFpEF)
Authors: Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz Journal: Nat Rev Dis Primers Date: 2018-10-25 Impact factor: 52.329
Authors: Eli Muchtar; Morie A Gertz; Shaji K Kumar; Grace Lin; Barry Boilson; Alfredo Clavell; Martha Q Lacy; Francis K Buadi; Suzanne R Hayman; Prashant Kapoor; David Dingli; S Vincent Rajkumar; Angela Dispenzieri; Martha Grogan Journal: Amyloid Date: 2018-03-12 Impact factor: 7.141
Authors: Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia Journal: Eur Heart J Date: 2015-07-28 Impact factor: 29.983
Authors: Erin Karlstedt; Victor Jimenez-Zepeda; Jonathan G Howlett; James A White; Nowell M Fine Journal: J Card Fail Date: 2019-01-18 Impact factor: 5.712
Authors: Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins Journal: Circulation Date: 2016-04-22 Impact factor: 29.690
Authors: A Yilmaz; J Bauersachs; F Bengel; R Büchel; I Kindermann; K Klingel; F Knebel; B Meder; C Morbach; E Nagel; E Schulze-Bahr; F Aus dem Siepen; N Frey Journal: Clin Res Cardiol Date: 2021-01-18 Impact factor: 5.460
Authors: Bernadet T Santema; Vicente Artola Arita; Iziah E Sama; Mariëlle Kloosterman; Maarten P van den Berg; Hans L A Nienhuis; Isabelle C Van Gelder; Peter van der Meer; Faiez Zannad; Marco Metra; Jozine M Ter Maaten; John G Cleland; Leong L Ng; Stefan D Anker; Chim C Lang; Nilesh J Samani; Kenneth Dickstein; Gerasimos Filippatos; Dirk J van Veldhuisen; Carolyn S P Lam; Michiel Rienstra; Adriaan A Voors Journal: Cardiovasc Res Date: 2022-08-24 Impact factor: 13.081